Information Provided By:
Fly News Breaks for November 27, 2017
BDSI
Nov 27, 2017 | 11:28 EDT
H.C. Wainwright analyst Oren Livnat noted that BioDelivery Sciences' pain drug Belbuca continues a steady upward trajectory, and believes that if lobbying efforts and initiatives addressing the opioid epidemic "result in more substantial changes to managed care access, CDC guidelines, or even FDA opioid labelling, there could be upside to long-term peak" for Belbuca sales. Livnat reiterated a Buy rating and $5 price target on BioDelivery Sciences shares.
News For BDSI From the Last 2 Days
There are no results for your query BDSI
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.